Characteristics and outcome of patients with ganglioneuroblastoma, nodular subtype: A report from the INRG project

European Journal of Cancer

Volumn 48, Issue 8, 2012, Pages 1185-1191

  Angelini, Paola ^a   London, Wendy B ^b   Cohn, Susan L ^c   Pearson, Andrew D J ^d   Matthay, Katherine K ^e   Monclair, Tom ^f   Ambros, Peter F ^g   Shimada, Hiroyuki ^h   Leuschner, Ivo ⁱ   Peuchmaur, Michel ^j   Irwin, Meredith S ^a   Baruchel, Sylvain ^a  

^a HOSPITAL FOR SICK CHILDREN   (Canada)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f OSLO UNIVERSITY HOSPITAL   (Norway)

^g ST ANNA CHILDREN S HOSPITAL   (Austria)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ UNIVERSITY OF KIEL   (Germany)

^j Institute of Pathology   (France)

more..

Author keywords

Cancer; Children; Neuroblastic tumours; Outcome; Prognostic factors

Indexed keywords

FERRITIN;

ARTICLE; CANCER STAGING; CANCER SURVIVAL; CHILD; EVENT FREE SURVIVAL; FERRITIN BLOOD LEVEL; GENE AMPLIFICATION; GENETIC TRAIT; HUMAN; MAJOR CLINICAL STUDY; NEUROBLASTOMA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT IDENTIFICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; RISK FACTOR; TUMOR DIFFERENTIATION;

AGE FACTORS; GANGLIONEUROBLASTOMA; HUMANS; INFANT; INFANT, NEWBORN; NEOPLASM STAGING; NUCLEAR PROTEINS; ONCOGENE PROTEINS; PLOIDIES;

EID: 84860432129     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.10.037     Document Type: Article

References (31)

1. J.M. Maris Recent advances in neuroblastoma N Engl J Med 362 23 2010 2202 2211
2. M. Peuchmaur, E.S. d'Amore, and V.V. Joshi Revision of the International Neuroblastoma Pathology Classification: confirmation of favorable and unfavorable prognostic subsets in ganglioneuroblastoma, nodular Cancer 98 10 2003 2274 2281
3. H. Shimada, I.M. Ambros, and L.P. Dehner Terminology and morphologic criteria of neuroblastic tumors: recommendations by the International Neuroblastoma Pathology Committee Cancer 86 2 1999 349 363
4. H. Shimada, I.M. Ambros, and L.P. Dehner The International Neuroblastoma Pathology Classification (the Shimada system) Cancer 86 2 1999 364 372
5. H. Shimada, J. Chatten, and W.A. Newton Jr. Histopathologic prognostic factors in neuroblastic tumors: definition of subtypes of ganglioneuroblastoma and an age-linked classification of neuroblastomas J Natl Cancer Inst 73 2 1984 405 416
6. S. Navarro, G. Amann, and K. Beiske Prognostic value of International Neuroblastoma Pathology Classification in localized resectable peripheral neuroblastic tumors: a histopathologic study of localized neuroblastoma European Study Group 94.01 Trial and Protocol J Clin Oncol 24 4 2006 695 699
7. S.L. Cohn, A.D. Pearson, and W.B. London The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report J Clin Oncol 27 2 2009 289 297
8. M.L. Schmidt, H.R. Salwen, and D. Chagnovich Evidence for molecular heterogeneity in human ganglioneuroblastoma Pediatr Pathol 13 6 1993 787 796
9. H. Shimada, S. Umehara, and Y. Monobe International neuroblastoma pathology classification for prognostic evaluation of patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group Cancer 92 9 2001 2451 2461
10. C. Okamatsu, W.B. London, and A. Naranjo Clinicopathological characteristics of ganglioneuroma and ganglioneuroblastoma: a report from the CCG and COG Pediatr Blood Cancer 53 4 2009 563 569
11. E. Kaplan, and P. Meier Nonparametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 481
12. A.B. Cantor Projecting the standard error of the Kaplan-Meier estimator Stat Med 20 14 2001 2091 2097
13. W.B. London, L. Boni, and T. Simon The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives Cancer Lett 228 1-2 2005 257 266
14. S. Goto, S. Umehara, and R.B. Gerbing Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors: a report from the Children's Cancer Group Cancer 92 10 2001 2699 2708
15. W.B. London, R.P. Castleberry, and K.K. Matthay Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group J Clin Oncol 23 27 2005 6459 6465
16. H. Christiansen, K. Sahin, and F. Berthold Comparison of DNA aneuploidy, chromosome 1 abnormalities, MYCN amplification and CD44 expression as prognostic factors in neuroblastoma Eur J Cancer 31A 4 1995 541 544
17. A. Canete, M. Gerrard, and H. Rubie Poor survival for infants with MYCN-amplified metastatic neuroblastoma despite intensified treatment: the International Society of Paediatric Oncology European Neuroblastoma Experience J Clin Oncol 27 7 2009 1014 1019
18. B. De Bernardi, M. Gerrard, and L. Boni Excellent outcome with reduced treatment for infants with disseminated neuroblastoma without MYCN gene amplification J Clin Oncol 27 7 2009 1034 1040
19. F. Bourdeaut, A. Ribeiro, and R. Paris In neuroblastic tumours, Schwann cells do not harbour the genetic alterations of neuroblasts but may nevertheless share the same clonal origin Oncogene 27 21 2008 3066 3071
20. S. Coco, R. Defferrari, and P. Scaruffi Genome analysis and gene expression profiling of neuroblastoma and ganglioneuroblastoma reveal differences between neuroblastic and Schwannian stromal cells J Pathol 207 3 2005 346 357
21. I.M. Ambros, A. Zellner, and B. Roald Role of ploidy, chromosome 1p, and Schwann cells in the maturation of neuroblastoma N Engl J Med 334 23 1996 1505 1511
22. P.F. Ambros, I.M. Ambros, and G.M. Brodeur International consensus for neuroblastoma molecular diagnostics: report from the International Neuroblastoma Risk Group (INRG) Biology Committee Br J Cancer 100 9 2009 1471 1482
23. R.E. George, W.B. London, and S.L. Cohn Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a Pediatric Oncology Group study J Clin Oncol 23 27 2005 6466 6473
24. J. Schneiderman, W.B. London, and G.M. Brodeur Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: a report from the Children's Oncology Group J Clin Oncol 26 6 2008 913 918
25. R. Bagatell, P. Rumcheva, and W.B. London Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy J Clin Oncol 23 34 2005 8819 8827
26. R. Bagatell, M. Beck-Popovic, and W.B. London Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the International Neuroblastoma Risk Group database J Clin Oncol 27 3 2009 365 370
27. J.M. Maris, C. Guo, and D. Blake Comprehensive analysis of chromosome 1p deletions in neuroblastoma Med Pediatr Oncol 36 1 2001 32 36
28. J.M. Maris, M.J. Weiss, and C. Guo Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study J Clin Oncol 18 9 2000 1888 1899
29. E.F. Attiyeh, W.B. London, and Y.P. Mosse Chromosome 1p and 11q deletions and outcome in neuroblastoma N Engl J Med 353 21 2005 2243 2253
30. R. Spitz, B. Hero, T. Simon, and F. Berthold Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma Clin Cancer Res 12 11, Pt. 1 2006 3368 3373
31. I. Janoueix-Lerosey, G. Schleiermacher, and E. Michels Overall genomic pattern is a predictor of outcome in neuroblastoma J Clin Oncol 27 7 2009 1026 1033